Beam Therapeutics Inc logo

BEAM - Beam Therapeutics Inc Share Price

$89.13 0.6  0.7%

Last Trade - 26/02/21

Sector
Healthcare
Size
Large Cap
Market Cap £3.74bn
Enterprise Value £3.60bn
Revenue £17.2k
Position in Universe 1342nd / 6715
Bullish
Bearish
Unlock BEAM Revenue
Momentum
Relative Strength (%)
1m -4.19%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -29.8%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.018 0.007 2.15
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, BeamTherapeutics Inc revenues increased 50% to $18K. Net lossapplicable to common stockholders increased 68% to $100.4M.Revenues reflect an increase in demand for the Company'sproducts and services due to favorable market conditions.Higher net loss reflects Research and development - Balancincrease from $31.3M to $65.2M (expense), General andadministrative - B increase of 45% to $18.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BEAM Revenue Unlock BEAM Revenue

Net Income

BEAM Net Income Unlock BEAM Revenue

Normalised EPS

BEAM Normalised EPS Unlock BEAM Revenue

PE Ratio Range

BEAM PE Ratio Range Unlock BEAM Revenue

Dividend Yield Range

BEAM Dividend Yield Range Unlock BEAM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BEAM EPS Forecasts Unlock BEAM Revenue
Profile Summary

Beam Therapeutics Inc. is a biotechnology company focused on developing precision genetic medicines based on its base editing technology, to providing life-long cures to patients suffering from diseases. Its base editing technology enables a new class of precision genetic medicines that targets a single base in the genome without making a double-stranded break in the deoxyribonucleic acid (DNA). It is advancing a broad, diversified portfolio of 12 base editing programs against distinct editing targets. Its programs are organized by delivery modality into three distinct pipelines: electroporation for delivery to blood cells and immune cells; lipid nanoparticles (LNPs), for non-viral in vivo delivery to the liver and potentially other organs in the future; and adeno-associated viral vectors (AAV), for viral delivery to the eye and central nervous system (CNS).

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated January 25, 2017
No. of Shareholders: 85
No. of Employees: 118
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 58,418,198
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BEAM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BEAM
Upcoming Events for BEAM
Frequently Asked Questions for Beam Therapeutics Inc
What is the Beam Therapeutics Inc share price?

As of 26/02/21, shares in Beam Therapeutics Inc are trading at $89.13, giving the company a market capitalisation of £3.74bn. This share price information is delayed by 15 minutes.

How has the Beam Therapeutics Inc share price performed this year?

Shares in Beam Therapeutics Inc are currently trading at $89.13 and the price has moved by 0.289k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Beam Therapeutics Inc price has moved by 0.200k% over the past year.

What are the analyst and broker recommendations for Beam Therapeutics Inc?

There are no analysts currently covering Beam Therapeutics Inc.

When will Beam Therapeutics Inc next release its financial results?

Beam Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Beam Therapeutics Inc dividend yield?

Beam Therapeutics Inc does not currently pay a dividend.

Does Beam Therapeutics Inc pay a dividend?

Beam Therapeutics Inc does not currently pay a dividend.

When does Beam Therapeutics Inc next pay dividends?

Beam Therapeutics Inc does not currently pay a dividend.

How do I buy Beam Therapeutics Inc shares?

To buy shares in Beam Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Beam Therapeutics Inc?

Shares in Beam Therapeutics Inc are currently trading at $89.13, giving the company a market capitalisation of £3.74bn.

Where are Beam Therapeutics Inc shares listed? Where are Beam Therapeutics Inc shares listed?

Here are the trading details for Beam Therapeutics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BEAM
What kind of share is Beam Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Beam Therapeutics Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Beam Therapeutics Inc share price forecast 2021?

Shares in Beam Therapeutics Inc are currently priced at $89.13. At that level they are trading at 7.15% discount to the analyst consensus target price of 0.00.

Analysts covering Beam Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.017 for the next financial year.

How can I tell whether the Beam Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Beam Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 0.227k%. At the current price of $89.13, shares in Beam Therapeutics Inc are trading at 88.95% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Beam Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Beam Therapeutics Inc.

Who are the key directors of Beam Therapeutics Inc?

Beam Therapeutics Inc's management team is headed by:

David Liu - CFD
J. Keith Joung - CFD
John Evans - CEO
Giuseppe Ciaramella - PRE
Christine Swenson - SVP
Manmohan Singh - SVP
Terry-Ann Burrell - CFO
Kristina Burow - IND
Graham Cooper - IND
Mark Fishman - IND
Carole Ho - IND
Kathleen Walsh - DRC
Who are the major shareholders of Beam Therapeutics Inc?

Here are the top five shareholders of Beam Therapeutics Inc based on the size of their shareholding:

ARCH Venture Partners Venture Capital
Percentage owned: 14.11% (8.24m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 12.55% (7.33m shares)
Redmile Group, LLC Investment Advisor/Hedge Fund
Percentage owned: 6.47% (3.78m shares)
Temasek Holdings Pte. Ltd. Sovereign Wealth Fund
Percentage owned: 5.74% (3.35m shares)
Liu (David R. Ph.D.) Individual Investor
Percentage owned: 5.58% (3.26m shares)
Similar to BEAM
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.